{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:58:55Z","timestamp":1790096335900,"version":"4.0.1"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI093484 - 01"],"award-info":[{"award-number":["1R01AI093484 - 01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201100028C"],"award-info":[{"award-number":["HHSN272201100028C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mSphere"],"published-print":{"date-parts":[[2017,2,22]]},"abstract":"<jats:p>\n            Rising resistance rates for macrolides, fluoroquinolones, and \u03b2-lactams in the most common pathogens associated with community-acquired bacterial pneumonia (CABP) are of concern, especially for cases of moderate to severe infections in vulnerable populations such as the very young and the elderly. New antibiotics that are active against multidrug-resistant\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            and\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            are needed for use in the empirical treatment of the most severe forms of this disease. TP-271 is a promising new fluorocycline antibiotic demonstrating\n            <jats:italic>in vitro<\/jats:italic>\n            potency and nonclinical efficacy by intravenous and oral administration against the major pathogens associated with moderate to severe CABP.\n          <\/jats:p>","DOI":"10.1128\/msphere.00004-17","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T17:57:42Z","timestamp":1487959062000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens"],"prefix":"10.1128","volume":"2","author":[{"given":"Trudy H.","family":"Grossman","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Fyfe","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Hackel","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Minyard","sequence":"additional","affiliation":[{"name":"Southern Research Institute, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken B.","family":"Waites","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Dubois","sequence":"additional","affiliation":[{"name":"M360, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Vivisource Laboratories, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Slee","sequence":"additional","affiliation":[{"name":"Vivisource Laboratories, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Weiss","sequence":"additional","affiliation":[{"name":"University of North Texas Health Science Center, Fort Worth, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/380488"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.275.2.134"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2102084"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"e_1_3_2_6_2","volume-title":"Antibiotic resistance threats in the United States, 2013","author":"CDC","year":"2013","unstructured":"CDC . 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.s2.5"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.6.3854"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2012.11.006"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/533594"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0908.030089"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700501"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq067"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/976273"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-015-0085-1"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis561"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf809"},{"key":"e_1_3_2_19_2","volume-title":"Mollicutes: molecular biology and pathogenesis","author":"Waites KB","year":"2014","unstructured":"Waites KB Lysynyansky I B\u00e9b\u00e9ar CM . 2014. Antibiotic susceptibility testing and resistance in mycoplasmas of humans and animals. InBrowningGCittiC (ed), Mollicutes: molecular biology and pathogenesis. Caister Academic Press, United Kingdom."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2108.150273"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00216-6"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.8.1829"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06187-11"},{"key":"e_1_3_2_24_2","volume-title":"Guidance for industry: microbiological data for systemic antibacterial drug products\u2014development, analysis, and presentation","author":"FDA","year":"2016","unstructured":"FDA . 2016. Guidance for industry: microbiological data for systemic antibacterial drug products\u2014development, analysis, and presentation. Guidance August 2016; US Department of Health and Human Services. FDA CDER. FDA, Silver Spring, MD."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/430352"},{"key":"e_1_3_2_26_2","first-page":"F 1","article-title":"In vitro activity of fluorocyclines against Legionella pneumophila","author":"Dubois J","year":"2010","unstructured":"Dubois J Dubois M Martel J Grossman T Sutcliffe J . 2010. In vitro activity of fluorocyclines against Legionella pneumophila. InAbstr 50th Intersci Conf Antimicrob Agents Chemother, Boston, MA, abstr F 1\u20132159.","journal-title":"Abstr 50th Intersci Conf Antimicrob Agents Chemother"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.femsle.2005.02.034"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.173.1.176-183.1991"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M409573200"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.172.12.6942-6949.1990"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1086"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1865-1871.2005"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf224"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"e_1_3_2_35_2","volume-title":"Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"CLSI","year":"2015","unstructured":"CLSI . 2015. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M07-A10, vol 32, no 2. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania.","edition":"10"},{"key":"e_1_3_2_36_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 25th informational supplement","author":"CLSI","year":"2015","unstructured":"CLSI . 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document m100-S25, vol 35. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_37_2","volume-title":"Manual of clinical microbiology","author":"Edelstein PH","year":"2007","unstructured":"Edelstein PH . 2007. Legionella, p 835\u2013849. InMurrayPBaronEJorgensenJHLandryMLPfallerMA (ed), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.","edition":"9"},{"key":"e_1_3_2_38_2","volume-title":"Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline","author":"CLSI","year":"2011","unstructured":"CLSI . 2011. Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline. CLSI document M43-A, vol 31, no 19. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780471729259.mc11b01s12"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"}],"container-title":["mSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mSphere.00004-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mSphere.00004-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T03:51:57Z","timestamp":1646711517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mSphere.00004-17"}},"subtitle":[],"editor":[{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2,22]]}},"alternative-id":["10.1128\/mSphere.00004-17"],"URL":"https:\/\/doi.org\/10.1128\/msphere.00004-17","relation":{},"ISSN":["2379-5042"],"issn-type":[{"value":"2379-5042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]},"assertion":[{"value":"2017-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00004-17"}}